Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2007, p. 1737-1740, Vol. 51, No. 5
0066-4804/07/$08.00+0 doi:10.1128/AAC.01542-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Genetic Basis of Resistance to Fusidic Acid in Staphylococci
A. J. O'Neill,1
F. McLaws,1
G. Kahlmeter,2
A. S. Henriksen,3 and
I. Chopra1*
Antimicrobial Research Centre and Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom,1
Department of Clinical Microbiology, Central Hospital, S-351 85 Växjö, Sweden,2
LEO Pharma, Industriparken 55, DK-2750 Ballerup, Copenhagen, Denmark3
Received 11 December 2006/
Returned for modification 26 January 2007/
Accepted 21 February 2007
Resistance to fusidic acid in Staphylococcus aureus often results from acquisition of the fusB determinant or from mutations in the gene (fusA) that encodes the drug target (elongation factor G). We now report further studies on the genetic basis of resistance to this antibiotic in the staphylococci. Two staphylococcal genes that encode proteins exhibiting ca. 45% identity with FusB conferred resistance to fusidic acid in S. aureus. One of these genes (designated fusC) was subsequently detected in all fusidic acid-resistant clinical strains of S. aureus tested that did not carry fusB or mutations in fusA, and in strains of S. intermedius. The other gene (designated fusD) is carried by S. saprophyticus, explaining the inherent resistance of this species to fusidic acid. Fusidic acid-resistant strains of S. lugdunensis harbored fusB. Thus, resistance to fusidic acid in clinical isolates of S. aureus and other staphylococcal species frequently results from expression of FusB-type proteins.
* Corresponding author. Mailing address: Antimicrobial Research Centre and Institute of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom. Phone: 44 113 343 5604. Fax: 44 113 343 5638. E-mail:
i.chopra{at}leeds.ac.uk
Published ahead of print on 26 February 2007.
Antimicrobial Agents and Chemotherapy, May 2007, p. 1737-1740, Vol. 51, No. 5
0066-4804/07/$08.00+0 doi:10.1128/AAC.01542-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Lannergard, J., Norstrom, T., Hughes, D.
(2009). Genetic Determinants of Resistance to Fusidic Acid among Clinical Bacteremia Isolates of Staphylococcus aureus. Antimicrob. Agents Chemother.
53: 2059-2065
[Abstract]
[Full Text]
-
Delgado, A., Zaman, S., Muthaiyan, A., Nagarajan, V., Elasri, M. O., Wilkinson, B. J., Gustafson, J. E.
(2008). The fusidic acid stimulon of Staphylococcus aureus. J Antimicrob Chemother
62: 1207-1214
[Abstract]
[Full Text]
-
McLaws, F., Chopra, I., O'Neill, A. J.
(2008). High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis. J Antimicrob Chemother
61: 1040-1043
[Abstract]
[Full Text]
-
Frank, K. L., del Pozo, J. L., Patel, R.
(2008). From Clinical Microbiology to Infection Pathogenesis: How Daring To Be Different Works for Staphylococcus lugdunensis. Clin. Microbiol. Rev.
21: 111-133
[Abstract]
[Full Text]
-
Vickers, A. A., Chopra, I., O'Neill, A. J.
(2007). Intrinsic Novobiocin Resistance in Staphylococcus saprophyticus. Antimicrob. Agents Chemother.
51: 4484-4485
[Abstract]
[Full Text]
-
Norstrom, T., Lannergard, J., Hughes, D.
(2007). Genetic and Phenotypic Identification of Fusidic Acid-Resistant Mutants with the Small-Colony-Variant Phenotype in Staphylococcus aureus. Antimicrob. Agents Chemother.
51: 4438-4446
[Abstract]
[Full Text]
-
Simor, A. E., Stuart, T. L., Louie, L., Watt, C., Ofner-Agostini, M., Gravel, D., Mulvey, M., Loeb, M., McGeer, A., Bryce, E., Matlow, A., and the Canadian Nosocomial Infection Surveillance,
(2007). Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals. Antimicrob. Agents Chemother.
51: 3880-3886
[Abstract]
[Full Text]